Differential effects of amyloid-beta 1-40 and 1-42 fibrils on 5-HT1A serotonin receptors in rat brain

Neurobiology of Aging

Volumn 40, Issue , 2016, Pages 11-21

  Verdurand, Mathieu ^a   Chauveau, Fabien ^a   Daoust, Alexia ^a,d   Morel, Anne Laure ^a   Bonnefoi, Frédéric ^b   Liger, François ^b   Bérod, Anne ^a   Zimmer, Luc ^a,b,c  

^a LYON NEUROSCIENCE RESEARCH CENTER   (France)

^b CERMEP IMAGERIE DU VIVANT   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

5 HT1A receptors; Alzheimer's disease; Amyloid beta peptides; Positron emission tomography; Serotonin

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; SEROTONIN 1A RECEPTOR; THIOFLAVINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; SEROTONIN 1 RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN; CELL MATURATION; CORPUS STRIATUM; DENTATE GYRUS; FIBER; GENE EXPRESSION; HIPPOCAMPUS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT; RECEPTOR BINDING; TRANSMISSION ELECTRON MICROSCOPY; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; DISEASE MODEL; INJECTION; METABOLISM; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; COGNITIVE DYSFUNCTION; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INJECTIONS; MALE; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN, 5-HT1;

EID: 84960468358     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.12.008     Document Type: Article

References (63)

1. Aletrino M.A., Vogels O.J., Van Domburg P.H., Ten Donkelaar H.J. Cell loss in the nucleus raphes dorsalis in Alzheimer's disease. Neurobiol. Aging 1992, 13:461-468.
2. Assal F., Cummings J.L. Neuropsychiatric symptoms in the dementias. Curr. Opin. Neurol. 2002, 15:445-450.
3. Aznavour N., Zimmer L. [18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain. Neuropharmacology 2007, 52:695-707.
4. Bagheri M., Joghataei M.T., Mohseni S., Roghani M. Genistein ameliorates learning and memory deficits in amyloid beta(1-40) rat model of Alzheimer's disease. Neurobiol. Learn. Mem. 2011, 95:270-276.
5. Beach T.G., Sue L.I., Walker D.G., Sabbagh M.N., Serrano G., Dugger B.N., Mariner M., Yantos K., Henry-Watson J., Chiarolanza G., Hidalgo J.A., Souders L. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. J. Alzheimers Dis. 2012, 28:869-876.
6. Becker G., Streichenberger N., Billard T., Newman-Tancredi A., Zimmer L. A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer's disease. CNS Neurosci. Ther. 2014, 20:930-934.
7. Bowen D.M., Francis P.T., Chessell I.P., Webster M.T. Neurotransmission-the link integrating Alzheimer research?. Trends Neurosci. 1994, 17:149-150.
8. Bowen D.M., Najlerahim A., Procter A.W., Francis P.T., Murphy E. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:9504-9508.
9. Braak H., Braak E., Bohl J. Staging of Alzheimer-related cortical destruction. Eur. Neurol. 1993, 33:403-408.
10. Chen C.P., Alder J.T., Bowen D.M., Esiri M.M., McDonald B., Hope T., Jobst K.A., Francis P.T. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J. Neurochem. 1996, 66:1592-1598.
11. Cheng K.T. 4-(2 -Methoxyphenyl)-1-[2 -(N-2 -pyridinyl)-p-[18F]fluorobenzamido]ethylpiperazine 2004, Molecular Imaging and Contrast Agent Database (MICAD), Bethesda (MD).
12. Couillard-Despres S., Winner B., Schaubeck S., Aigner R., Vroemen M., Weidner N., Bogdahn U., Winkler J., Kuhn H.G., Aigner L. Doublecortin expression levels in adult brain reflect neurogenesis. Eur. J. Neurosci. 2005, 21:1-14.
13. Cross A.J. Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann. N. Y. Acad. Sci. 1990, 600:405-415. discussion 15-7.
14. Cross A.J., Crow T.J., Ferrier I.N., Johnson J.A. The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurobiol. Aging 1986, 7:3-7.
15. D'Amato R.J., Zweig R.M., Whitehouse P.J., Wenk G.L., Singer H.S., Mayeux R., Price D.L., Snyder S.H. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann. Neurol. 1987, 22:229-236.
16. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277:32046-32053.
17. de Sousa Abreu R., Penalva L.O., Marcotte E.M., Vogel C. Global signatures of protein and mRNA expression levels. Mol. Biosyst. 2009, 5:1512-1526.
18. Halliday G.M., McCann H.L., Pamphlett R., Brooks W.S., Creasey H., McCusker E., Cotton R.G., Broe G.A., Harper C.G. Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathol. 1992, 84:638-650.
19. Hirst W.D., Cheung N.Y., Rattray M., Price G.W., Wilkin G.P. Cultured astrocytes express messenger RNA for multiple serotonin receptor subtypes, without functional coupling of 5-HT1 receptor subtypes to adenylyl cyclase. Brain Res. Mol. Brain Res. 1998, 61:90-99.
20. Ishibashi K., Ishiwata K., Toyohara J., Murayama S., Ishii K. Regional analysis of striatal and cortical amyloid deposition in patients with Alzheimer's disease. Eur. J. Neurosci. 2014, 40:2701-2706.
21. Kepe V., Barrio J.R., Huang S.C., Ercoli L., Siddarth P., Shoghi-Jadid K., Cole G.M., Satyamurthy N., Cummings J.L., Small G.W., Phelps M.E. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:702-707.
22. Kia H.K., Brisorgueil M.J., Hamon M., Calas A., Verge D. Ultrastructural localization of 5-hydroxytryptamine1A receptors in the rat brain. J. Neurosci. Res. 1996, 46:697-708.
23. Klein A.M., Kowall N.W., Ferrante R.J. Neurotoxicity and oxidative damage of beta amyloid 1-42 versus beta amyloid 1-40 in the mouse cerebral cortex. Ann. N. Y. Acad. Sci. 1999, 893:314-320.
24. Klunk W.E., Price J.C., Mathis C.A., Tsopelas N.D., Lopresti B.J., Ziolko S.K., Bi W., Hoge J.A., Cohen A.D., Ikonomovic M.D., Saxton J.A., Snitz B.E., Pollen D.A., Moonis M., Lippa C.F., Swearer J.M., Johnson K.A., Rentz D.M., Fischman A.J., Aizenstein H.J., DeKosky S.T. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 2007, 27:6174-6184.
25. Koivunen J., Verkkoniemi A., Aalto S., Paetau A., Ahonen J.P., Viitanen M., Nagren K., Rokka J., Haaparanta M., Kalimo H., Rinne J.O. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008, 131(Pt 7):1845-1853.
26. Lai M.K., Tsang S.W., Alder J.T., Keene J., Hope T., Esiri M.M., Francis P.T., Chen C.P. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology 2005, 179:673-677.
27. Lai M.K., Tsang S.W., Francis P.T., Esiri M.M., Keene J., Hope T., Chen C.P. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003, 974:82-87.
28. Lanctot K.L., Hussey D.F., Herrmann N., Black S.E., Rusjan P.M., Wilson A.A., Houle S., Kozloff N., Verhoeff N.P., Kapur S. A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease. Am. J. Geriatr. Psychiatry 2007, 15:888-898.
29. Le Bars D., Lemaire C., Ginovart N., Plenevaux A., Aerts J., Brihaye C., Hassoun W., Leviel V., Mekhsian P., Weissmann D., Pujol J.F., Luxen A., Comar D. High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. Nucl. Med. Biol. 1998, 25:343-350.
30. Lorke D.E., Lu G., Cho E., Yew D.T. Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 2006, 7:36.
31. Maier T., Guell M., Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett. 2009, 583:3966-3973.
32. Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., Kupfer D.J., Reynolds C.F. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 1998, 18:407-430.
33. Mizukami K., Ishikawa M., Akatsu H., Abrahamson E.E., Ikonomovic M.D., Asada T. An immunohistochemical study of the serotonin 1A receptor in the hippocampus of subjects with Alzheimer's disease. Neuropathology 2011, 31:503-509.
34. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harbor Perspect. Med. 2012, 2:a006338.
35. Nilsson M.R. Techniques to study amyloid fibril formation in vitro. Methods 2004, 34:151-160.
36. Noristani H.N., Olabarria M., Verkhratsky A., Rodriguez J.J. Serotonin fibre sprouting and increase in serotonin transporter immunoreactivity in the CA1 area of hippocampus in a triple transgenic mouse model of Alzheimer's disease. Eur. J. Neurosci. 2010, 32:71-79.
37. Ogren S.O., Eriksson T.M., Elvander-Tottie E., D'Addario C., Ekstrom J.C., Svenningsson P., Meister B., Kehr J., Stiedl O. The role of 5-HT(1A) receptors in learning and memory. Behav. Brain Res. 2008, 195:54-77.
38. Palacios J.M., Waeber C., Hoyer D., Mengod G. Distribution of serotonin receptors. Ann. N. Y. Acad. Sci. 1990, 600:36-52.
39. Patel T.D., Zhou F.C. Ontogeny of 5-HT1A receptor expression in the developing hippocampus. Brain Res. Dev. Brain Res. 2005, 157:42-57.
40. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, 6, illustrated, Academic Press, Cambridge, Massachusetts, USA, 2007.
41. Payne S.H. The utility of protein and mRNA correlation. Trends Biochem. Sci. 2015, 40:1-3.
42. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 1993, 13:1676-1687.
43. Pompeiano M., Palacios J.M., Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 1992, 12:440-453.
44. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
45. Ramirez M.J., Lai M.K., Tordera R.M., Francis P.T. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status. Drugs 2014, 74:729-736.
46. Reinikainen K.J., Soininen H., Riekkinen P.J. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J. Neurosci. Res. 1990, 27:576-586.
47. Reynolds G.P., Arnold L., Rossor M.N., Iversen L.L., Mountjoy C.Q., Roth M. Reduced binding of [3H]ketanserin to cortical 5-ht2 receptors in senile dementia of the Alzheimer type. Neurosci. Lett. 1984, 44:47-51.
48. Riad M., Garcia S., Watkins K.C., Jodoin N., Doucet E., Langlois X., el Mestikawy S., Hamon M., Descarries L. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J. Comp. Neurol. 2000, 417:181-194.
49. Rodriguez J.J., Noristani H.N., Verkhratsky A. The serotonergic system in ageing and Alzheimer's disease. Prog. Neurobiol. 2012, 99:15-41.
50. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
51. Sato S., Mizukami K., Asada T. A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Int. J. Neuropsychopharmacol. 2007, 10:281-283.
52. Schechter L.E., Smith D.L., Rosenzweig-Lipson S., Sukoff S.J., Dawson L.A., Marquis K., Jones D., Piesla M., Andree T., Nawoschik S., Harder J.A., Womack M.D., Buccafusco J., Terry A.V., Hoebel B., Rada P., Kelly M., Abou-Gharbia M., Barrett J.E., Childers W. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Pharmacol. Exp. Ther. 2005, 314:1274-1289.
53. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
54. Stargardt A., Swaab D.F., Bossers K. The storm before the quiet: neuronal hyperactivity and Abeta in the presymptomatic stages of Alzheimer's disease. Neurobiol. Aging 2015, 36:1-11.
55. Truchot L., Costes N., Zimmer L., Laurent B., Le Bars D., Thomas-Anterion C., Mercier B., Hermier M., Vighetto A., Krolak-Salmon P. A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease. Neuroimage 2008, 40:1251-1256.
56. Truchot L., Costes S.N., Zimmer L., Laurent B., Le Bars D., Thomas-Anterion C., Croisile B., Mercier B., Hermier M., Vighetto A., Krolak-Salmon P. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology 2007, 69:1012-1017.
57. Verdurand M., Berod A., Le Bars D., Zimmer L. Effects of amyloid-beta peptides on the serotoninergic 5-HT1A receptors in the rat hippocampus. Neurobiol. Aging 2011, 32:103-114.
58. Villemagne V.L., Ataka S., Mizuno T., Brooks W.S., Wada Y., Kondo M., Jones G., Watanabe Y., Mulligan R., Nakagawa M., Miki T., Shimada H., O'Keefe G.J., Masters C.L., Mori H., Rowe C.C. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch. Neurol. 2009, 66:1537-1544.
59. Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012, 13:227-232.
60. Whitaker-Azmitia P.M., Clarke C., Azmitia E.C. Localization of 5-HT1A receptors to astroglial cells in adult rats: implications for neuronal-glial interactions and psychoactive drug mechanism of action. Synapse 1993, 14:201-205.
61. Wu Q.Y., Li J., Feng Z.T., Wang T.H. Bone marrow stromal cells of transgenic mice can improve the cognitive ability of an Alzheimer's disease rat model. Neurosci. Lett. 2007, 417:281-285.
62. Zheng M., Liu J., Ruan Z., Tian S., Ma Y., Zhu J., Li G. Intrahippocampal injection of Abeta1-42 inhibits neurogenesis and down-regulates IFN-gamma and NF-kappaB expression in hippocampus of adult mouse brain. Amyloid 2013, 20:13-20.
63. Zweig R.M., Ross C.A., Hedreen J.C., Steele C., Cardillo J.E., Whitehouse P.J., Folstein M.F., Price D.L. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann. Neurol. 1988, 24:233-242.